Oral Sessions
Click on the presentation title in red to see the abstract... (after the meeting only)
June 3, 2004
|
|
9:00-10:30: Session HIV, Virology
Chairs: Christine Rouzioux, Catherine Tamalet
- How to Manage Cross-resistance ?
- OP 1.3-Resistance to PI: Luc Perrin (Geneva, Switzerland),
Denis Lacoste
(Bordeaux, France)
- OP 1.6-Analysis of HIV-2 Resistance to Protease Inhibitors: Nogueira R, Coelho, S, Freitas-Vieira A , Mammano F, Goncalves J. URIA – Unidade de Retrovirologia e Doenças Infecciosas Associadas, University of Lisbon,Faculty of Pharmacy (Lisbon, Portugal) ; Laboratoire de Recherche Antivirale, INSERM U
82
,(Paris, France)
- OP 1.7-Polymorphism and Drug-selected Mutations in the Protease Gene of HIV-1 in Naive and Multi-treated Patient Isolates from the Seine-Saint-Denis District in France: differences between B and non-B subtypes: Hawajri AL, Gault E, Aloui C, Drugan T, Le Gal F, Dziri-Mendil S, Dény P. Laboratoire de bactériologie, virologie et hygiène, Hôpital Avicenne, AP-HP, EA3406 ATHSCO, UFR SMBH, Université Paris 13 (Bobigny, France) ; University of Medicine and Farmacy (Cluj, Romania)
|
14:00-15:00: Session HIV, ARV Strategies
Chairs: Stéfano Vella, José Gatell
17:00-18:00: Session HIV, Immunology
Chairs: Giuseppe Pantaléo, Jean-François Delfraissy
- OP 3.1-HAART-induced Immune Reconstitution: limitations & prospects: Giuseppe Pantaléo (Geneva, Switzerland)
- OP 3.2-New Insights into Immune Reconstitution : Marie-Lise Gougeon (Paris, France)
- OP 3.3-State of the Art of anti-HIV Immunotherapy:
Giuseppe
Tambussi
(Milano, Italy)
- OP 3.4-The Future of HIV Vaccine Development: Richard Koup (Bethesda, USA)
- OP 3.5-Humoral Immune Response Monitoring in HIV-1-infected Patients under anti-Tat Therapeutic Vaccine Trials: Zagury D, Le Buanec H, Badran BM, Willard-Gallo KE, Burny A and Gallo RC Université P et M Curie ; Néovacs (Paris, France) ; ULB (Bruxelles, Belgium) ; Institute of Human Virology (Baltimore, USA)
18:00-18:30: Special Lecture
SL 1.1-HIV Reservoirs: implications for therapy
Roger Pomerantz (Philadelphia, USA)
June 4, 2004
8:30-10:30: Session HIV, Pharmacology & New Drugs
Chairs: Gilles Peytavin, Caroline Solas
- OP 4.1-Optimal Use of TDM in ARV Therapy: David Burger (Amsterdam, The Netherlands)
- OP 4.2-The Search for New ARV Drugs: Erik Declercq (Leuven, Belgium)
- OP 4.3-New ARV in the Gilead Pipeline: Jim Rooney (Foster City, USA)
- OP 4.4-TMC 114, a new PI: Eric Lefebvre (Yardley, USA)
- OP 4.5-UK 427, 857: a promosing new drug: Chris Hitchcock (Sandwich, UK)
- OP 4.6-BMS 488043, a new attachment inhibitor: Richard Colonno (Wallingford, USA)
- OP 4.7-PA 457, a novel anti-HIV drug candidate: Carl Wild (Gaithersburg, USA)
- OP 4.8-SPD 754, a new RTI: Richard Bethell (Laval, Quebec)
14:00-15:00: Session HIV, HAART, Adverse Effects
Chairs: Pascale Leclercq, Alain Lafeuillade
- OP 5.1-Management of Metabolic Complications of ARV Therapy : Morrie Schambelan (San Francisco, USA)
- OP 5.2-Update on HAART-induced Lipodystrophy : Jacqueline Capeau (Paris, France)
- OP 5.3-In vitro Suppression of the Lipogenic Pathway by the non-nucleoside Reverse Transcriptase Inhibitor Efavirenz in 3T3 and Human Preadipocytes or Adipocytes : El Hadri K, Glorian M, Monsempes C, Dieudonné MN, Pecquery R, Giudicelli Y, Andreani M, Dugail I, Fčve B. UMR CNRS 7079 (Paris, France)
- Panel Discussion
17:00-17:30: Special Lecture
SL 1.2-New Concepts in anti-HIV Therapy
Robert Gallo (Baltimore, USA)
|
17:30-19:00: Session, HIV in a Widened Europe
Chairs: Yves Mouton, Emmanuel Delbeke
|
June 5, 2004
8:15-09:45: Session Viral Hepatitis
Chairs: Jean-Marie Lang, Vicente Soriano
- OP 7.2-Treatment of HIV-HCV coinfection: Vicente Soriano (Madrid, Spain)
- OP 7.3-Tolerance of Viral Hepatitis Therapy in HIV-infected Patients: Gilles Pialoux (Paris, France)
- OP 7.4-Role of the Hepatitis C Virus Coinfection on Humoral Immune Alterations on HIV-infected Patients on HAART: Soriano-Sarabia N, Molina-Pinelo S, Delgado-Pecellin C, de Felipe B, Sanchez-Quijano A, Lissen, Leal EM, Vallejo A. Group for the Study of Viral Hepatitis and AIDS, Hospital Universitario Virgen del Rocio, Seville, Spain
- OP 7.5-Liver Transplantation In Five HIV-infected Patients With Virus Hepatitis Induced Cirrhosis: Radecke K, Frühauf NR, Miller M, Ross B, Köditz R, Malago M, Treichel U, Broelsch CE, Gerken G. Department of Gastroenterology and Hepatology, Department of General Surgery and Transplantation, University Hospital Essen (Essen, Germany)
|
10:15-12:00: Free Oral Presentations, Basic ScienceChairs: Catherine Tamalet, Jean-Pierre de Jaureguiberry
- OP 8.1-NF90ctv, a cellular dsRNA binding Protein Inhibits the Rev-dependent Export of HIV-1 RNA:Castańo ME, Kumar A and Urcuqui-Inchima S. Immunovirology Laboratory, Faculty of Medicine, University of Antioquia (Medellín, Colombia)
- OP 8.2-Expression of HIV-1 gp160 in Transgenic Animals: Berrada F, Al Akhawayn University in Ifrane. School of Science & Engineering (
Ifrane
,
Morocco
)
- OP 8.3-Polymorphisms in CCR5 promoter are associated with rare HIV-1 infection of the D32/D32 homozygous individuals: Xihau Lu, Ghalib Alkhatib, R. Tubiana and L. Meyer .
Indiana
University
School
of Medicine,
Indianapolis
(
Indiana
,
USA
)
- OP 8.4-Evaluation of Porcine Thymic Xenografts to Restore Human Thymopoiesis that is Resistant to HIV Infection: Hadidi S, Damrauer S, Lan P, Yang YG, Sykes M. Massachusetts General Hospital, Harvard Medical School (Boston, USA)
- OP 8.5-Pol mutations and polymorphisms associated with NRTI and NNRTI-based regimens in Batswana patients infected with HIV-1 C: Doualla-Bell F,Gaseitsiwe S, Ndung'u T, Modukanele M, Peter T, Novitsky V, Ndwapi N, Gaolathe T, Avalos A, Wester W, Bussmann H, Cardiello P, Marlink R, Moffat H, Thior I, Essex M, Wainberg MA. McGill AIDS Centre- McGill University (Montreal, Canada) Botswana-Harvard Partnership for HIV Research and Education (Gaborone, Botswana), Harvard School of Public Health (Boston, USA)
- OP 8.6-Aminoglycoside-arginine Conjugates: chemical barriers of HIV-1 entry: Lapidot A and Borkow G. Department of Organic Chemistry, Weizmann
Institute
of
Science
, (
Rehovot
,
Israel
)
- OP 8.7-Pharmacological Blockade of Receptors Connecting To Inhibitory Pathways Of Immune Cells May Be An Efficient Immunopotentiating Treatment Of HIV/AIDS: Peuschel KE. Independent Researcher (
Lugano
,
Switzerland
)
- OP 8.8-Structure of Viral Antitermination Complexes: Schwarz S, Scheckenhofer U, Prasch S, Eisenmann A, Schweimer K, Wöhrl B, & Rösch P. Lehrstuhl für Biopolymere, University (
Bayreuth
,
Germany
)
- OP 8.9-The VirtualPhenotypeTM Analysis of an HIV-1 Genotype Provides a More Accurate Prediction of Drug Susceptibility Than a Single Phenotype Measurement: Van Houtte M, Vermeiren H, Lecocq P, Winters B, Pattery T, Mc Kenna P, Bacheler L. Virco BVBA (Mechelen, Belgium); VircoLab Inc, (Durham, USA)
|
10:15-12:00: Free Oral Presentations, Clinical ScienceChairs: Jean-Albert Gastaut, Alain Lafeuillade
- OP 9.1-Chinese SARS and AIDS Control at Frontier Ports: Mingchang S, Yonggui L, Yuping H. Madiandonglu Haidian District (
Beijing
, P.R..
China
)
- OP 9.2-HIV-1 subtypes in the Northern Border Region of Kenya: Lihana RW, Lwembe RM, Kiptoo MK, Ochieng W, Oishi I, Ichimura H, Songok EM. Kenya Medical Research Institute,
Jomo
Kenyatta
University
of Technology, KEMRI/JICA Project,
Nairobi
,
Kenya
- OP 9.3-Method of Treatment of Acquired Immune Deficiency Syndrome with Embryonic Hempatopoietic Stem Cells: Smikodub OI. Cell Therapy Clinic of
National
Medical
University
and Embryonic
Tissues
Center
EmCell
(Kiev,
Ukraine )
- OP 9.4-Andrieu unjustly disregarded. Better CD4-counts with Prednisolone: Ulmer A, Mueller M, Frietsch B. HIV-Practice (
Stuttgart
,
Germany
)
- OP 9.5-Enhanced Immunogenicity of HIV-1 Whole Killed Vaccine in Association with Amplivax*: Trabattoni D, Clivio A, Gori A, Bartholomew R, Fernandez-Cruz E, Lowry P, Kandimalla ER, Sullivan T, Bhagat L, Agrawal S, Clerici M, TheofanG, Bray DH. Dept Immunol, Dept Biol, Milano University, Dept Infect Dis (Milano, Italy); MRC Clinical Trials Unit (London, UK); Gregorio Maraon Univ Hospital (Madrid, Spain); Hybridon, Inc, Cambridge, Immune Response Co (Carlsbad, USA)
- OP 9.6-ESAT-6 and CFP-10 derived peptides for diagnosis of TB infection in severely immunocompromized HIV-infected individuals: Fortis C, Tasca S, Mantegani P, Lazzarin A, Scarpellini P. IRCCS San Raffaele,(Milano, Italy)
- OP 9.7-Why the Patient's Perspective is Critical in the Management of Lipodystrophy? : Duracinsky M, Cervoni J, Bourgarit A, Sereni D, Molina JM, Wu A, Chassany O. Hopital de Bicêtre; Hopital Lariboisiere, Hopital Saint-Louis (
Paris
,
France)
;
Johns
Hopkins
University
(
Baltimore
,
USA )
- OP 9.8-A Technological Monitoring and Management-Support System for Anti-Retroviral Therapy in South Africa: Introducing Cell-Life: Anand S, Rivett U. Cell-Life,
University of Cape Town
(C
ape Town,
South Africa )
|
|
12:00-13:00: Session Update on SARS
Chairs: Alain Lafeuillade, Gilles Hittinger
- OP 10.4-Detection & Quantification of the SARS-associated coronavirus: Leondios Kostrikis (Nicosia, Cyprus)
- OP 10.5-Concentration and Detection of SARS Coronavirus in Sewage from Xiao Tang Shan Hospital and the 309th Hospital of the Chinese PLA: Li J, Wang XW, Chao FH, Li J, Zhen B, Kong Q, Son N, Jin M, Xiao W, Gu C, Yin J, Wei W. Institute of Hygiene and Environmental Medicine, Academy of Military Medical Sciences, P.R. China; Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences (Beijing, P.R. China)
- OP 10.6-Purification, Characterization, and Immunogenicity of a Truncated Form of the SARS Spike Protein: Toward a recombinant glycoprotein subunit vaccine: Kan E, Coates S, Stadler K, Matsuoka K, Calderon E, Song H, Seo MY, Wininger M, Barnett S, Ulmer J, Rappuoli R, Abrignani S, Houghto, M, Han J, Srivasta I. Chiron Corporation (Emeryville, USA); IRIS, Chiron S.r.l. (Siena, Italy)
|
14:15-15:30: Session Concerns in HIV Care
Chairs: Alain Lafeuillade, Alain Rieu
|
|
